The major finding of the study, "Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice," found that the company's RVX101 vaccine candidate used to immunize a unique mouse line was shown to provide highly protective immunity and prevent herpes-associated neovascularization.
The protective efficacy of a live-attenuated HSV type 1 (HSV-1) vaccine, HSV-1 was evaluated in mice prophylactically in response to ocular HSV-1 challenge. Mice vaccinated with the HSV-1 0ΔNLS were found to be more resistant to subsequent ocular virus
In summary, RVx201 appears to be safe in guinea pigs, as it did not produce observable signs of disease, did not establish detectable latency, and did not produce recurrences. RVx202 produced minor injection site inflammation, viral shedding in vaginal secretions at early time points following vaginal inoculation (but not following intradermal inoculation) but did not establish detectable latency or produce recurrences.